Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca AbfiledCriticalAstrazeneca Ab
Priority to CU20100129ApriorityCriticalpatent/CU20100129A7/en
Publication of CU20100129A7publicationCriticalpatent/CU20100129A7/en
La invención se refiere a los compuestos bicíclicos de fórmula I ESPACIO PARA LA FÓRMULA donde los números enteros X1, X2, X3, el Anillo A, R4, R5 y m son como los definidos en la descripción. La presente invención también se relaciona con procesos para la preparación de tales compuestos, composiciones farmacéuticas que los contienen y su uso en la fabricación de un medicamento para su uso en la prevención o tratamiento de afecciones asociadas con el receptor de andrógeno.The invention relates to the bicyclic compounds of formula I SPACE FOR FORMULA where the integers X1, X2, X3, Ring A, R4, R5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of conditions associated with the androgen receptor.
CU20100129A2010-06-212010-06-21
BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF AFFECTIONS ASSOCIATED WITH THE ANDROGEN RECEIVER
CU20100129A7
(en)
Compounds derived from diphenyl-pyrazolopyridines, modulators of the nuclear receptor nurr-1; intermediate compounds; pharmaceutical composition; and its use for the treatment and prevention of neurodegenerative diseases, brain trauma, inflammatory diseases, osteoporosis, cancer, among others.
Compounds derived from 2-oxo-alkyl-1-piperazin-2-one, related by the p75ntr receptors; procedure for preparing the compounds; intermediate compound; drug and pharmaceutical composition comprising one of the compounds; and its use in the preparation of useful drugs to treat neurodegenerative diseases.